| 引用本文: | 任艳玲,杨泽锐,李金贤,李雄.药物基因多态性对PD-1/PD-L1抑制剂抗癌疗效及不良反应影响的研究进展[J].中国现代应用药学,2024,41(22):139-146. |
| renyanling,yangzerui,lijinxian,Lixiong.Research progress on the effects of gene polymorphism on the anticancer efficacy and adverse reactions of PD-1/PD-L1 inhibitors[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(22):139-146. |
|
| 摘要: |
| 目前,靶向PD-1/ PD-L1轴的免疫检查点抑制剂已成为各种癌症的热点治疗方法。尽管一些患者接受PD-1/ PD-L1抑制剂治疗显著提高了长期生存率,但患者之间存在着较大的个体差异,一部分患者对其表现出原发性耐药,总体有效率大概仅在20-30%。药物基因组学研究表明,单核苷酸多态性(SNPs)是影响药物疗效和药物不良反应的最关键因素之一。本文综述了基因多态性对PD-1/ PD-L1抑制剂的抗肿瘤疗效及免疫相关不良反应的影响,为今后的研究提供了方向。 |
| 关键词: PD-1/PD-L1抑制剂 药物基因组学 基因多态性 免疫相关不良反应 |
| DOI： |
| 分类号: |
| 基金项目:国家自然基金青年科学基金项目（82304657）;中央财政医疗服务与保障能力提升资金（No.Z155080000004） ;广东省医学科研基金项目(B2021243); 广东省医院药师青年托举研究基金（晴粤药学基金）（No.2023QNTJ36） |
|
| Research progress on the effects of gene polymorphism on the anticancer efficacy and adverse reactions of PD-1/PD-L1 inhibitors |
|
renyanling1, yangzerui2, lijinxian1, Lixiong1
|
|
1.Guangdong Pharmaceutical University;2.The First Affiliated Hospital of Guangdong Pharmaceutical University
|
| Abstract: |
| At present, immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have become a hot treatment for various cancers. Although PD-1/PD-L1 inhibitor therapy in some patients significantly improves long-term survival, there are large individual differences between patients, and some patients show primary resistance, and the overall response rate is only about 20-30%. Pharmacogenomics studies have shown that single nucleotide polymorphisms (SNPs) are one of the most critical factors affecting drug efficacy and adverse drug reactions. This article reviews the effects of gene polymorphisms on the anti-tumor efficacy and immune-related adverse reactions of PD-1/PD-L1 inhibitors, which provides direction for future research. |
| Key words: PD-1/PD-L1 inhibitors pharmacogenomics gene polymorphisms Immune-related adverse effects |
